Cancer Genetics Buying Indian Firm BioServe for $1.9M; Q1 Revenues up 17 Percent | GenomeWeb

NEW YORK (GenomeWeb) – Cancer Genetics today announced an agreement to buy Indian genomics and next-generation sequencing services firm BioServe Biotechnologies for $1.9 million, primarily in stock and other deferred considerations.

The Rutherford, NJ-based cancer genetics testing firm also reported a 17 percent increase in its first quarter revenues.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.